Alpha Tau reports 100% response rate for Alpha DaRT plus Keytruda in head and neck cancer study
DRTS•Safety and next steps
Safety appeared manageable, with no serious side effects attributed to Alpha DaRT reported in the treated group.
Recruitment is complete; the company is discussing a similar, larger U.S. study with the FDA.
Study results from head and neck cancer trial
Alpha Tau reported positive results from a study of Alpha DaRT with Merck’s Keytruda in elderly patients with advanced head and neck cancer.
Results were presented in a podium session at the American Head and Neck Society meeting in Boston on July 21, 2026.
All evaluable patients responded to treatment, beating the trial’s pre-set success bar and supporting the company’s combination strategy in metastatic disease.
